Key Takeaways & Executive Findings
- •• • Astrocyte-derived PDGF and LIF are essential for oligodendrocyte survival; in vitro studies show that blocking these factors reduces OLG viability by >50%, underscoring the need to maintain astrocyte-OLG signaling for effective remyelination. • • Astrocyte activation via STAT3 signaling determines the balance between oligodendrocyte and Schwann cell remyelination; STAT3 knockout mice exhibit a 2-fold increase in Schwann cell remyelination, indicating that STAT3 is a critical switch that can be targeted to favor CNS remyelination. • • Microglial M1/M2 polarization differentially regulates neuroinflammation; M1 microglia release pro-inflammatory cytokines that inhibit OPC differentiation by up to 70%, while M2 microglia promote remyelination, highlighting the therapeutic potential of modulating microglial polarization. • • Astrocytes enhance exosomal secretion from OPCs via integrin β4-mediated adhesion, increasing OPC proliferation by approximately 40%; this mechanism represents a scalable target for boosting endogenous OPC pools in demyelinating lesions.
China Biomedical & Cell Therapy Radar
Get verified English translations, SEM micrographs & open-access PDF alerts from China's leading state key laboratories delivered to your inbox every Monday at 08:00 EST.
Abstract
Demyelinating diseases of the central nervous system (CNS) are characterized by failed remyelination, largely due to arrested oligodendrocyte precursor cell (OPC) differentiation. This review synthesizes evidence on the crosstalk between oligodendrocytes (OLGs) and other glial cells—astrocytes, microglia, and neurons—in the context of demyelination. OLGs, the myelin-forming cells of the CNS, are essential for axonal integrity and saltatory conduction. Under pathological conditions, factors including astrocyte-derived PDGF and leukemia inhibitory factor (LIF), microglial polarization states, and neuronal activity modulate OLG survival, metabolic support, and process outgrowth. Astrocytes promote process outgrowth via basic fibroblast growth factor (bFGF) and extracellular matrix interactions, while also regulating iron metabolism and exosomal secretion from OPCs through integrin β4-mediated adhesion. Microglial heterogeneity, with M1/M2 polarization, influences neuroinflammation and remyelination outcomes. The review highlights that astrocyte activation via STAT3 signaling determines the balance between oligodendrocyte and Schwann cell remyelination. These intercellular interactions significantly impact myelin regeneration and offer potential therapeutic targets. Modulating these interactions at specific temporal stages may provide novel strategies for treating demyelinating diseases and related neurological conditions. The integration of single-cell resolution data on microglial heterogeneity and spatial-temporal dynamics is critical for developing targeted interventions.
1. Introduction
Demyelinating diseases such as multiple sclerosis (MS) affect over 2.8 million people worldwide, with current therapies primarily targeting immune suppression rather than myelin repair. The failure of endogenous remyelination is a major bottleneck, largely attributed to the arrested differentiation of oligodendrocyte precursor cells (OPCs) within chronic lesions. Despite decades of research, no approved therapy effectively restores myelin sheaths, leaving patients with progressive disability. The complexity of the CNS microenvironment, particularly the interactions between oligodendrocytes and other glial cells, has been underappreciated as a therapeutic target.
This review addresses the critical gap by systematically analyzing the crosstalk network between oligodendrocytes, astrocytes, microglia, and neurons. It synthesizes evidence that astrocytic factors (PDGF, LIF, bFGF), microglial polarization states, and neuronal activity collectively dictate OPC differentiation and remyelination success. By elucidating these interactions at the molecular level—such as STAT3 signaling in astrocytes and integrin β4-mediated exosomal secretion—the review provides a framework for developing combinatorial therapies that target multiple glial cell types simultaneously. This integrated approach may overcome the limitations of single-cell-targeted strategies and accelerate the translation of remyelination therapies.
Loading authentic research manuscript (Pages 1–5)...
HE Jiayi, SUN Qingqing, LI Xiaowen, DU Ruoyan, XUE Haoran, ZHANG Yuan, LI Xing (2025). Oligodendrocyte Interactions with Glial Cells and Neurons in Demyelinating Disease. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2025105
Research & Educational Purpose Only: The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioDataare intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the primary molecular mechanism by which astrocytes regulate oligodendrocyte survival, and what are the quantitative effects?
Astrocytes secrete PDGF and leukemia inhibitory factor (LIF), which directly support oligodendrocyte survival. In vitro studies demonstrate that neutralizing PDGF or LIF reduces oligodendrocyte viability by over 50% (Gard et al., Development 1995). This indicates that astrocyte-derived trophic support is non-redundant and essential for maintaining oligodendrocyte populations, particularly under demyelinating stress.
How does STAT3 signaling in astrocytes influence the balance between oligodendrocyte and Schwann cell remyelination, and what are the therapeutic implications?
Astrocyte-specific STAT3 activation promotes oligodendrocyte remyelination but suppresses Schwann cell remyelination. In STAT3 knockout models, Schwann cell remyelination increases twofold, suggesting that STAT3 is a critical determinant of remyelinating cell fate (Monteiro de Castro et al., Am J Pathol 2015). Targeting STAT3 could bias repair toward oligodendrocyte-mediated remyelination, which is more efficient for CNS axons.
What role does microglial polarization play in remyelination, and what are the quantitative impacts on OPC differentiation?
M1-polarized microglia release pro-inflammatory cytokines (e.g., TNF-α, IL-1β) that inhibit OPC differentiation by up to 70%, whereas M2-polarized microglia secrete anti-inflammatory factors that promote remyelination (Tang and Le, Mol Neurobiol 2016). Modulating the M1/M2 balance, for example via TGF-β1 or IL-4, could enhance endogenous repair.
How do astrocytes enhance OPC proliferation via exosomal secretion, and what is the magnitude of this effect?
Astrocytes stimulate OPCs to secrete exosomes through integrin β4-mediated cell adhesion, which in turn promotes OPC proliferation by approximately 40% (Zhang et al., Biochem Biophys Res Commun 2020). This paracrine loop represents a scalable mechanism to expand OPC pools in demyelinated lesions, potentially overcoming the limited availability of OPCs for remyelination.
What are the key challenges in translating glial cell interaction targets into clinical therapies for demyelinating diseases?
The major challenges include the spatial and temporal heterogeneity of glial responses, the risk of off-target effects when modulating broadly expressed pathways (e.g., STAT3), and the difficulty of achieving sufficient CNS penetration with biologics. Additionally, the dual role of microglia (protective vs. detrimental) necessitates precise targeting. Combinatorial approaches that simultaneously modulate astrocytes, microglia, and OPCs at specific disease stages are likely required, but dosing and timing optimization remain unresolved.
Related Chinese Research & Cross-Citations
miR-199a-3p suppresses Vldlr expression to promote cardiomyocyte proliferation
The proliferative capacity of cardiomyocytes is limited in adult mammals, and replacing lost tissue following acute ischemic injury is challenging. Previous studies have demonstrated that miR-199a-3p can promote cardiomyocyte proliferation, but the exact mechanism by which this occurs remains unclear, although multiple targets of miR-199a-3p have been identified. We recently showed that very-low-density-lipoprotein receptor (Vldlr) inhibits cardiomyocyte proliferation, and in this study we aim to test whether Vldlr is a functional target gene of miR-199a-3p. 3′UTR reporter assays demonstrate that miR-199a-3p directly binds to the 3′UTR of Vldlr and inhibits its translation. Overexpressing Vldlr blunts the pro-proliferative effect of miR-199a-3p on cardiomyocytes, suggesting that Vldlr is indeed a functional target of miR-199a-3p. Mechanistically, Vldlr reduces S807/811 phosphorylation of RB1, and inhibiting CDK4/6 to prevent RB1 phosphorylation can block the pro-proliferative effect of both Vldlr knockdown and miR-199a-3p, suggesting that RB1 phosphorylation is required for the cardiomyocyte proliferation induced by miR-199a-3p and Vldlr knockdown. The findings of this study reveal Vldlr as a novel functional target of miR-199a-3p in cardiomyocytes and identify RB1 as a downstream effector of cardiomyocyte proliferation. The identification of the role of the miR-199a-3p-Vldlr-RB1 axis in cardiomyocyte proliferation may provide potential therapeutic targets for cardiac regenerative medicine.
A positive feedback loop between FOSB and miR-133b controls colon cancer cell proliferation
FOSB, a member of the FOS gene family, forms heterodimers with JUN family proteins to engage in diverse cellular processes. Its biological impacts vary among different types of tumors, yet its specific function in colon cancer (CC) remains ambiguous. In this study, quantitative real-time PCR (qRT-PCR) and immunohistochemistry (IHC) are applied to measure FOSB expression levels, followed by an analysis of the association between FOSB expression and patients’ clinical parameters. In vitro experiments are performed to assess cell proliferation, including growth rate, cell cycle distribution, and apoptosis. A subcutaneous xenograft model in nude mice is utilized to monitor tumor growth in vivo. Additionally, chromatin immunoprecipitation (ChIP) and luciferase reporter assays are conducted to dissect the interactions among FOSB, miR-133b, and POU2F1. The results indicate that FOSB expression is downregulated in CC tissues relative to normal controls. Overexpression of FOSB suppresses proliferation and promotes apoptosis in CC cells. Mechanistically, FOSB binds to the promoter region of miR-133b, enhancing its transcription and subsequently repressing POU2F1 expression. Notably, decreased POU2F1 expression also alleviates the transcriptional repression of the FOSB promoter region, establishing a FOSB-miR-133b-POU2F1 feedback loop that inhibits CC proliferation. In summary, our findings suggest that FOSB acts as a tumor suppressor gene in CC and may exert its inhibitory effects on CC growth via the FOSB-miR-133b-POU2F1 feedback loop.
Reduced expression of the PER2 protein contributes to β1-AA-induced cardiac autophagy rhythm disorders
Heart failure may be linked to fluctuations in the rhythm of autophagy in cardiomyocytes throughout the day. Circadian rhythms depend on the regulation of core biological clock proteins, with PER2 playing a crucial role. Our previous research confirmed that the presence of β1-adrenergic receptor autoantibodies (β1-AAs) could inhibit myocardial autophagy, leading to cell death and heart failure. However, it remains unclear whether β1-AA induces cardiac autophagy rhythm disorders by affecting PER2 expression. In this study, we find that β1-AA disrupts the autophagy rhythm in cardiomyocytes, which is primarily indicated by decreased expression of the autophagy marker protein LC3. β1-AA disrupts the rhythmic expression of the PER2 protein in myocardial cells, which is manifested mainly by a decrease in PER2 protein expression. Metoprolol is used to verify that the β1-adrenergic receptor contributes to the reduction in the Per2 protein caused by β1-AA. Knockdown of Per2 with lentivirus reduces the inhibition of LC3 expression caused by β1-AA, whereas overexpression of Per2 in cardiomyocytes using lentivirus significantly restores the β1-AA-induced decrease in LC3 expression. Moreover, mTORC1 activation is found to participate in β1-AA-induced autophagy inhibition in cardiomyocytes after pretreatment with the mTORC1 inhibitor rapamycin. Furthermore, the decreased expression of the PER2 protein caused by β1-AA disrupts the myocardial autophagy rhythm by promoting mTORC1 activation through lentiviruses that knock down or overexpress the Per2 gene. This study provides an experimental basis for the precise treatment of cardiovascular diseases from the perspective of biological rhythm.
A protein-RNA complex orchestrated by EMB1006, EMB1270, EMB976, and CFM2 facilitates clpP1 intron 2 splicing in Arabidopsis chloroplasts
In Arabidopsis, the PPR proteins EMB1006, EMB1270, and EMB976 are all essential for the splicing of plastid clpP1 intron 2 (clpP1.2), although each also targets other distinct RNAs. The precise mechanism underlying their co-ordinated action in clpP1.2 splicing remains unclear. In this study, RNA electrophoretic mobility shift assays, guided by PPR code prediction, confirm that EMB1006 specifically binds to a sequence near the 3′ end of clpP1 exon 2. Additionally, immunoprecipitation coupled with mass spectrometry reveals that EMB1006 forms a complex with EMB1270, EMB976, and CFM2. Direct interactions between EMB1006 and EMB1270 or CFM2 are further supported by yeast two-hybrid (Y2H) and semi-in vivo pull-down assays. However, no direct interactions between EMB976 and EMB1006, CFM2 or EMB1270 are detected by Y2H. Based on these findings and previous evidence that EMB1270 binds to clpP1 intron 2 and interacts with CFM2, we propose a model in which EMB1006 and EMB1270 bind to distinct sites on clpP1 pre-mRNA. Together with CFM2 and possible indirect association with EMB976, they assemble into a protein-RNA complex that facilitates the splicing of clpP1.2 in chloroplasts.
Tanshinones from Salvia miltiorrhiza alleviate ulcerative colitis via reprogramming the gut microbiota-metabolite axis
The anti-inflammatory properties of the traditional herb Salvia miltiorrhiza Bunge are well-established, yet its precise mechanism of action in ulcerative colitis (UC) remains unclear. Herein, we evaluate the therapeutic potential of four major tanshinones–tanshinone IIA (Tan IIA), miltirone, neocryptotanshinone, and dihydrotanshinone I–in a murine dextran sulfate sodium (DSS)-induced colitis model. Our results show that tanshinones effectively alleviate disease severity, suppress systemic and local inflammation, and restore intestinal barrier integrity. Integrated multi-omics analysis reveals that the therapeutic efficacy originates from a comprehensive reprogramming of the gut microbiota-metabolite axis. Specifically, tanshinones reverse colitis-associated dysbiosis and rectify metabolic disturbances in linoleic acid metabolism, bile acid biosynthesis, and amino acid utilization. Correlation network analysis identifies key functional modules linking beneficial microbes (e.g., Akkermansia) to anti-inflammatory lipid mediators and associating pathobionts (e.g., Desulfovibrio) with disrupted bile acid metabolism. Notably, supplementation with Akkermansia muciniphila synergizes with Tan IIA to amplify barrier restoration and metabolic normalization. Our findings establish that tanshinones ameliorate UC through microbiota-driven metabolic reprogramming, wherein the restructured microbial community actively shapes a therapeutic metabolic output. This work elucidates a metabolite-mediated mechanism of action and positions tanshinones as promising microbiome-targeting therapeutics for inflammatory bowel disease.
Distinct miR319a identified from Persicaria chinensis mediates cross-kingdom suppression of cervical cancer by targeting ITGA3
Persicaria chinensis, a well-known traditional Chinese medicinal herb that is both edible and medicinal, has been widely acknowledged for its therapeutic effects, such as anti-inflammatory, antioxidant, and antitumor activities. However, the role of miRNAs from this plant in the cross-kingdom regulation of human diseases has not been investigated. In this study, we analyze the miRNA expression profile of P. chinensis using high-throughput sequencing and identify a total of 673 miRNAs, including 422 novel miRNAs that are unique to this plant and 251 conserved miRNAs. Among the conserved miRNAs, pch-miR319a is found to be the most abundant. Moreover, food-oriented pch-miR319a accumulates in the uterus and tumors and exhibits a rich repertoire of target genes within cancer-related pathways, demonstrating significant cross-kingdom regulatory potential. Utilizing the dual-luciferase reporter gene assay, we demonstrate that pch-miR319a from P. chinensis targets the Itga3 gene, which is associated with cervical cancer progression. Overexpression of pch-miR319a significantly decreases the viability, migration, and induces apoptosis of HeLa cervical cancer cells in vitro. Moreover, in a syngeneic mouse tumor model of cervical cancer, treatment with pch-miR319a effectively inhibits tumor growth and downregulates the expressions of ITGA3 and the proliferation marker Ki-67. Our study highlights the potential of pch-miR319a from P. chinensis as a novel therapeutic agent for cervical cancer by targeting ITGA3 and provides new insights into the cross-kingdom regulatory mechanisms of plant miRNAs in human diseases.